Navigation Links
Widening Application Range to Boost MRI Markets in Eastern Europe, Says Frost & Sullivan
Date:10/13/2009

LONDON, Oct. 13 /PRNewswire/ -- Eastern Europe is poised to be the market to tap into in the near future for magnetic resonance imaging (MRI) manufacturers. These countries have budgets allocated to improve their healthcare systems after becoming members of the European Union (EU). Their installed base of MRI systems is not large, which directly makes this region conducive for market growth. At the same time, market prospects will receive a boost from an expanding application range.

(LOGO: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.medicalimaging.frost.com), Western and Eastern European Markets for MRI, finds that the market earned revenues of $858.2 million in 2008 and estimates this to reach $996.3 million in 2012. The market sectors covered in this research include cardiovascular MRI, breast MRI, functional MRI, interventional MRI, contrast-enhanced MRI, spinal MRI and musculoskeletal MRI.

"Along with constant upgrades in Tesla strength, the number of applications of MRI is increasing from a research point of view," notes Frost & Sullivan Research Analyst Gideon Praveen Kumar. "Moreover, such applications are becoming commercially viable as well."

For most applications, a 1.5 Tesla system, coupled with the use of CAD, will suffice. 3-Tesla systems provide a higher resolution of images, which can prove to be important, especially for more sophisticated clinical applications. MRI scanning has also been used for ophthalmic and other sensory applications, making this a preferred route for dedicated MRI vendors.

However, reimbursement remains an industry-wide constraint for the medical imaging industry. Reimbursement for MRI scans is of considerable importance as it has one of the highest costs per procedure.

"Medical practitioners, while willing to refer more patients for MRI scans, are deterred from doing so by the low reimbursement levels which are around $500 to $800," explains Kumar. "The MRI market is particularly vulnerable to fluctuations in reimbursement levels."

Moreover, regulatory agencies worldwide prohibit individuals with implantable cardiac devices from receiving MRI scans. This further threatens market expansion.

Accordingly, cardiovascular MRI manufacturers should work towards the development of automated coil-changing systems. At the same time, they should focus on enhancing image-reconstruction techniques.

Promisingly, 3-Tesla systems are expected to grow better than projected a few years back as they do not have the inherent technical problems that they posed when first launched.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, a brochure will be sent to you by e-mail.

Western and Eastern European Markets for MRI is part of the Medical Imaging Growth Partnership Services programme, which also includes research in the following markets: Eastern European Ultrasound Market, European Medical Imaging Equipment Market for Cardiology Applications and Eastern European Medical Imaging Modalities. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

Western and Eastern European Markets for MRI

M3C6

    Contact:
    Katja Feick
    Corporate Communications - Europe
    P: +49 (0) 69 7703343
    E: katja.feick@frost.com
    http://www.frost.com

SOURCE Frost & Sullivan


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
2. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
3. Indevus Announces Submission of New Drug Application
4. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
5. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
6. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
7. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
8. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
9. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
10. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
11. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)...  Alopexx Oncology, LLC announced data from a Phase ... (immunocytokine) composed of interleukin-2 and a CD20-targeting monoclonal antibody. ... cells as Rituxan and maintains the activities of both ... in tumor targeting, engagement of the immune system, and ... the study (abstract #95954) were presented at the 58 ...
(Date:12/6/2016)... Dec. 6, 2016 Homozygous Familial ... Summary Global Markets Direct,s latest ... Familial Hypercholesterolemia (HoFH) – Pipeline Review, H2 ... Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline landscape. ... disorder which is caused due to mutation ...
(Date:12/6/2016)... 6, 2016   AlloSource , one of ... skin and soft-tissue allografts for use in surgical ... Manager, for being named to the Board of ... Award by the Commerce Department,s National Institute of ... to process excellence. The Baldrige Award is the ...
Breaking Medicine Technology:
(Date:12/7/2016)... (PRWEB) , ... December 07, ... ... Technologies, announced its newest portable bioelectronic medicine device WellnessPro Plus for consumers ... Plus substantially enhances the WellnessPro platform by expanding the treatment modalities available ...
(Date:12/7/2016)... ... ... “Tomorrow Trump Goes To Washington”: a brief but engaging illustration depicting the ... “Tomorrow Trump Goes To Washington” is the creation of published author, Nancy Engestrom, a ... Nancy attributes her patriotic nature to her WWII veteran father. She says, “I ...
(Date:12/7/2016)... NORFOLK, Va. (Dec. 3, 2016) , ... (PRWEB) ... ... the nation’s only patient advocacy nonprofit for individuals impacted by cerebral cavernous angiomas, ... work in New Mexico with a patient engagement program. New Mexico has more ...
(Date:12/7/2016)... ... 2016 , ... NuevaCare, a leading home care agency based in San Mateo ... pages as part of its ambitious website relaunch. As Bay Area clients scramble to ... agencies serving their city. The new site has several key city-specific pages to address ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... collaborate in developing a vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). ... available in South Korea for emergency deployment in the event of a future ...
Breaking Medicine News(10 mins):